Cost-effectiveness of once daily GLP-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway.

@article{Huetson2015CosteffectivenessOO,
  title={Cost-effectiveness of once daily GLP-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway.},
  author={Pernilla Huetson and James L. Palmer and Andr{\'e}e Levorsen and Marie Fournier and Maeva Germ{\'e} and Euan McLeod},
  journal={Journal of medical economics},
  year={2015},
  volume={18 8},
  pages={573-85}
}
BACKGROUND Lixisenatide is a potent, selective and short-acting once daily prandial glucagon-like peptide-1 receptor agonist which lowers glycohemoglobin and body weight by clinically significant amounts in patients with type 2 diabetes treated with basal insulin, with limited risk of hypoglycemia. OBJECTIVE To assess the cost-effectiveness of… CONTINUE READING